 ARC-HIF0 is an RNAi-based therapeutic designed to reduce the production of hypoxia-inducible factor 0α (HIF-0α) to treat clear cell renal cell carcinoma. It is the first drug candidate using a new DPC™ delivery vehicle designed to target tissues outside of the liver. Arrowhead is conducting tumor models and is working on manufacturing scale up for the new delivery vehicle to support advancement of ARC-HIF0 into IND-enabling studies. 